08/07/2015Molecular Imaging Technologies, LLC (“MIT”) successfully acquires Affiliated PET Systems, LLC (“APS”).  The acquisition of APS by MIT will have no name change.  The facility will continue to operate under the APS name and logo and there will be no disruption to day to day operations.  APS will continue to provide outstanding PET/CT and Diagnostic CT imaging to its physicians, patients, and the community.  APS offers excellent PET/CT and Diagnostic CT imaging, scheduling, pre-certification and billing, physician/patient education, certified clinical staff, FREE patient transportation to APS, translation services for patients receiving PET/CT scans, and quality programs to enhance physician/patient satisfaction.

Patient Testimonials 

  • “Melissa and Brittany made this such a pleasant experience, they are a great team and very professional”
  • “Very friendly service”
  • “…your Tech, Aaron, is the core that makes the person truly comfortable, relaxed, and without fear”

Statements from satisfied patients (2018)

News/Clinical Trials/Research 

  • 09/2018 – APS Earns CT Reaccreditation by the IAC – APS has been granted a three-year term of accreditation by the Intersocietal Accreditation Commission (IAC) in CT in the area(s) of Body CT. This latest accreditation awarded to APS demonstrates the facility’s ongoing commitment to providing quality patient care in CT.  Accreditation by IAC indicates that APS has undergone an intensive application and review process and is found to be in compliance with the published Standards, thus demonstrating a commitment to quality patient care in CT. 
  • 01/2018 – APS to begin Using Ga-68 DOTATATE FDA approved new diagnostic imaging agent to detect rare neuroendocrine tumors. 68Ga-DOTATATE PET/CT has demonstrated superiority in lesion detection compared to Octreoscan, MIBG scintigraphy and MRI. 
  • 12/2017 – APS begins performing PET/CT imaging with Axumin™ (fluciclovine F 18) injection which is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. 
  • 02/2017 – APS awarded a 3-year term of accreditation by the American College of Radiology (“ACR”) for Oncology (PET Services). The ACR gold seal of accreditation represents the highest level of image quality and patient safety. It is awarded only to facilities meeting ACR Practice Parameters and Technical Standards after a peer-review evaluation by board-certified physicians and medical physicists who are experts in the field. Image quality, personnel qualifications, adequacy of facility equipment, quality control procedures and quality assurance programs are assessed. 
  • 2017 – APS has recently been engaged by The Center for Rheumatology and Bone Research to be the preferred facility to participate in a new FDG clinical research study.  All of the clinical trial study medications being used in the clinical trial (DMARD triple therapy vs Enbrel vs Humira) are FDA approved for Rheumatoid Arthritis. 
  • 01/2016 – APS launches the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study. The 3 isotopes approved for the study are Neuraceq, Amyvid, and Vizamyl. The IDEAS Study will focus on brain images called amyloid PET scans which can show if amyloid plaques are building up in the brain. The presence or absence of amyloid plaques will help doctor’s determine the likelihood that patient’s symptoms are caused by Alzheimer’s disease. 
  • 09/2012 – APS begins to offer Amyvid® for PET/CT imaging of the brain to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer’s Disease (AD) and other causes of cognitive decline. 
  • 2011 – APS begins participation in the NOPR for Sodium Fluoride (NaF-18) which is a highly sensitive bone seeking PET tracer used for detection of skeletal abnormalities. The uptake mechanism is similar to Tc-99m MDP, but with better physical characteristics for imaging.